Search results for "Umbilical cord."

showing 10 items of 88 documents

Energy Metabolism Analysis of Three Different Mesenchymal Stem Cell Populations of Umbilical Cord Under Normal and Pathologic Conditions

2020

AbstractHuman umbilical cord mesenchymal stem cells (hUC-MSCs) are a pivotal source of therapeutically active cells for regenerative medicine due to their multipotent differentiation potential, immunomodulatory and anti-inflammatory proprieties, as well as logistical collection advantages without ethical concerns. However, it remains poorly understood whether MSCs from different compartments of the human umbilical cord are therapeutically superior than others. In this study, MSCs were isolated from Wharton’s jelly (WJ-MSCs), perivascular region (PV-MSCs) and cord lining (CL-MSCs) of hUC. These cells expressed the mesenchymal markers (CD90, CD73), stemness marker (OCT4), endothelial cell adh…

Wharton’s JellyCell Survivalmedicine.medical_treatmentBioenergeticIschemic diseaseBiologyBioenergeticsUmbilical cordArticleUmbilical CordIschemic diseasesWharton's jellymedicineHumansUmbilical cord mesenchymal stem cellWharton JellyPerivascularCell ShapeStem cell therapyUmbilical cord mesenchymal stem cellsMesenchymal stem cellMesenchymal Stem CellsStem-cell therapyCord liningCell biologyMitochondriaEndothelial stem cellStrokemedicine.anatomical_structureCD146Stem cellEnergy MetabolismBiomarkers
researchProduct

Perinatal stem cells revisited: directions and indications at the crossroads between tissue regeneration and repair.

2013

Perinatal stem cells research attracted great interest worldwide in recent years. Foetus-associated tissues contain various populations of stem cells, most of which are comprised within the category of mesenchymal stem cells (MSCs). This special issue collects both reviews and original reports on all the perinatal stem cell types which are currently under investigation. These cells have multiple promising features: differentiative capacity towards mature cell types of all the three germ layers, hypoimmunogenicity in vitro and in vivo, ease of sourcing, ex vivo culture and stor- age. In particular, immune modulation is viewed as a prom- ising feature of many MSCs populations, since these cel…

Wound HealingAmniotic fluidTissue EngineeringSettore BIO/16 - Anatomia UmanaStem CellsPlacentaWharton's jellyImmune modulationInfant NewbornAmniotic membranePerinatal stem cellUmbilical cord bloodAmniotic epitheliumRegenerative medicineHumansAmniotic epithelium; Amniotic fluid; Amniotic membrane; Immune modulation; Mesenchymal stem cells; Perinatal stem cells; Placenta; Regenerative medicine; Tissue repair; Umbilical cord; Umbilical cord blood; Wharton's jellyTissue repairUmbilical cordMesenchymal stem cell
researchProduct

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct

Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs).

2019

Adipose tissue is now on the top one of stem cell sources regarding its accessibility, abundance, and less painful collection procedure when compared to other sources. The adipose derived stem cells (ADSCs) that it contains can be maintained and expanded in culture for long periods of time without losing their differentiation capacity, leading to large cell quantities being increasingly used in cell therapy purposes. Many reports showed that ADSCs-based cell therapy products demonstrated optimal efficacy and efficiency in some clinical indications for both autologous and allogeneic purposes, hence becoming considered as potential tools for replacing, repairing, and regenerating dead or dama…

bone marrowmedicine.medical_treatmentAdipose tissueregenerative medicineBone Marrow CellsReviewMesenchymal Stem Cell TransplantationRegenerative medicinestem cell therapyCatalysisUmbilical CordInorganic ChemistryCell therapylcsh:ChemistryADSCsMedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5Spectroscopymesenchymal stem cellsbusiness.industryOrganic ChemistryMesenchymal stem cellCell DifferentiationGeneral MedicineStem-cell therapyStromal vascular fractionComputer Science Applicationsadipose tissueadipose derived stem cellsmedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Cancer researchBone marrowStem cellbusinessInternational journal of molecular sciences
researchProduct

Younger is better? Isolation and phenotypical characterization of mesenchymal stem cells from the Wharton's jelly of pre-term human umbilical cords

2014

full term umbilical cords TUC PTUC pre-term umbilical cords WJ-MSC CD29 CD44 CD73 CD90 CD 105 MHC I B7-H3.Settore BIO/16 - Anatomia Umana
researchProduct

Wharton’s jelly mesenchymal stem cells differentiation into hepatocyte-like cells: functional characterization and expression of immunomodulatory mol…

2015

Mesenchymal stem cells derived from Wharton’s jelly (WJ-MSCs) recently emerged as promising tools for cellular therapy due to their ability to differentiate into diverse cell types and their immunomodulatory features. Little is known on the expression of immunomodulatory molecules in mature cells differentiated from WJ-MSCs, therefore we aimed to characterize the extent of maintenance of the naive traits of these cells also in a highly specialized differentiated counterpart. WJ-MSCs were differentiated into hepatocyte-like cells (HLCs) with a four weeks protocol. RT-PCR, flow cytometry, IHC and ICC were performed to assess expression of key markers in both undifferentiated and differentiate…

hepatocyte differentiationmesenchymal stem cellsimmune modulationUmbilical cord; perinatal stem cells; mesenchymal stem cells; hepatocyte differentiation; immune modulation.Settore BIO/16 - Anatomia UmanaWharton's jellyperinatal stem cellcell therapyUmbilical cordliver
researchProduct

Cell differentiation markers in human umbilical cord; an immunohistochemical study

2011

The full-term human umbilical cord is made of three blood vessels (two arteries and a vein) surrounded by the Wharton’s jelly, a soft connective tissue made of few mesenchymal stromal cells and an abundant extracellular matrix. Both endothelial and Wharton’s jelly cells are versatile in their differentiation potential; they have shown to be able to differentiate into several cell lineages. Since the differentiation potential of these cells is very wide, we thought it could be interesting to investigate the expression of several cell differentiation markers in the different regions of human umbilical cord. Immunohistochemistry showed the expression of E-cadherin and cytokeratins in the amnio…

human umbilical cord differentiation markers
researchProduct

INFECTIOUS COMPLICATIONS AFTER UMBILICAL CORD-BLOOD TRANSPLANTATION FROM UNRELATED DONORS

2016

Umbilical cord-blood (UCB) is a well-recognized alternative source of stem cells for unrelated donor hematopoietic stem cell transplantation (HSCT). As compared with other stem cell sources from adult donors, it has the advantages of immediate availability of cells, absence of risk to the donor and reduced risk of graft-versus-host disease despite donor-recipient HLA disparity. However, the use of UCB is limited by the delayed post-transplant hematologic recovery due, at least in part, to the reduced number of hematopoietic cells in the graft and the delayed or incomplete immune reconstitution. As a result, severe infectious complications continue to be a leading cause of morbidity and mort…

lcsh:RC633-647.5Umbilical Cord Blood Transplantationbusiness.industryIncidence (epidemiology)medicine.medical_treatmentReview Articlelcsh:Diseases of the blood and blood-forming organsHematologyHuman leukocyte antigenDiseaseHematopoietic stem cell transplantation: umbilical cord-blood transplantation infectious bacterial fungal viral03 medical and health sciencesHaematopoiesisfluids and secretions0302 clinical medicineInfectious DiseasesImmune system030220 oncology & carcinogenesisImmunologymedicineStem cellbusiness030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Free and sulfoconjugated dehydroepiandrosterone, cyclic adenosine-3′,5′-monophosphate, and free estriol in maternal and cord blood

1976

When free DHEA, its sulfatide, and sulfate were assayed in maternal plasma as well as in umbilical cord arterial and venous plasma, rather high concentrations were found in either fraction from cord arterial plasma, reflecting the fetal contribution not only of free DHEA and DHEA sulfate, but also of the lipophile steroid sulfatide. Since high DHEA levels were associated with elevated c-AMP concentrations, a certain interrelationship of both parameters is indicated. In the course of delivery, a rapid decrease of free estriol in maternal plasma was observed. Higher concentration of free estriol in umbilical venous plasma pointed at its placental biosynthesis from fetal precursors.

medicine.medical_specialtyCordmedicine.medical_treatmentDehydroepiandrosteroneUmbilical cordSteroidCellular and Molecular NeurosciencePregnancyInternal medicineCyclic AMPpolycyclic compoundsmedicineHumansMolecular BiologyPharmacologyFetusLabor ObstetricSulfoglycosphingolipidsEstriolSulfatesChemistryVenous PlasmaEstriolDehydroepiandrosteroneCell BiologyFetal BloodEndocrinologymedicine.anatomical_structureCord bloodMolecular MedicineFemalehormones hormone substitutes and hormone antagonistsExperientia
researchProduct

Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-contro…

2020

AbstractBACKGROUNDTreatment of severe Corona Virus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.METHODSIn this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned to receive either UC-MSCs (4 × 107 cells per infusion) or placebo on day 0, 3, and 6. The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28. Other imaging outcomes, 6-minute walk test, maximum vital capaci…

medicine.medical_specialtyLungbusiness.industryIncidence (epidemiology)PlaceboGastroenterologyUmbilical cordmedicine.anatomical_structureInternal medicineDiffusing capacityClinical endpointmedicineStem cellAdverse effectbusiness
researchProduct